Anti Tumor Activity of the Novel Arginase Inhibitor AZD0011 in Syngeneic Tumor Models, & Tumor Genetics Shape the Immune Landscape in Humanized Mouse Models

Time: 1:30 pm
day: Day One


  • Developed a novel arginase inhibitor, AZD0011 that in vivo shows a time and dose dependent PK and PD and several signs of immune activation
  • AZD0011 shows single agent anti-tumor activity in various syngeneic tumor models and can be combined with various therapies including checkpoint inhibitors
  • Development of humanized mouse models show distinct immune subset engraftment in bone marrow and spleen, and robust engraftment in PDX tumors